Latest:
Dr Hu on Choosing Between Bispecific Antibodies vs CAR T-Cell Therapy in DLBCL
Marie Hu, MD, discusses her decision-making process when considering bispecific antibodies vs CAR T-cell therapy in patients with DLBCL.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Arya Roy, MBBS
Arya Roy, MBBS, is an assistant professor in the Division of Oncology at The Ohio State University College of Medicine
Latest:
Antibody Drug Conjugates in Breast Cancer: Breakthroughs and Adverse Effects
Arya Roy, MBBS, discusses breakthroughs and adverse effects associated with antibody-drug conjugates in breast cancer.
Senthil Damodaran, MD, PhD
Latest:
Dr Damodaran on Futibatinib Plus Fulvestrant in FGFR1-Amplified HR+/HER2– Breast Cancer
Senthil Damodaran, MD, PhD, discusses the efficacy of futibatinib plus fulvestrant in patients with FGFR1-amplified metastatic hormone receptor–positive, HER2-negative breast cancer according to findings from the phase 2 FOENIX-MBC2 trial.
Joseph Barbi, PhD
Latest:
Investigators Seek to Resolve the “Obesity Paradox” in Lung Cancer
Smoking is associated with the most widely known cancer causing carcinogen across the world. However, a second, more insidious factor has been increasingly recognized for its role in promoting cancer growth: obesity.
Joanna M. Rhodes, MD, MSCE
Latest:
Recognizing BTKi Resistance in CLL—Incorporating Pirtobrutinib in Relapsed/Refractory Disease
Panelists discuss how Bruton tyrosine kinase (BTK) resistance mutation testing is routinely performed at disease progression, but currently doesn’t change treatment decisions because pirtobrutinib shows comparable efficacy regardless of mutation status. However, high-level mutations (C481S or L528W) might favor venetoclax-based therapy over pirtobrutinib in second-line treatment. The panelists also emphasize the importance of patient education; approximately one-third of progressive patients lack detectable resistance mutations yet still require treatment changes based on clinical progression rather than molecular findings.